Therapeutic cyclopentane derivatives

1. A compound represented by the formula

or a pharmaceutically acceptable salt thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof with up to 14 carbon atoms; or Y is hydroxymethyl or an ether thereof with up to 14 carbon atoms; or Y is a tetrazolyl functional group;

A is —(CH 2 ) 6 —, cis-CH 2 CH═CH—(CH 2 ) 3 —, or —CH 2 C≡C—(CH 2 ) 3 —, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH 2 ) m —Ar—(CH 2 ) o — wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein one CH 2 may be replaced by S or O; and

B is substituted aryl or substituted heteroaryl.

2. The compound of claim 1 wherein Y is selected from CO 2 R 2 , CON(R 2 ) 2 , CON(OR 2 )R 2 , CON(CH 2 CH 2 OH) 2 , CONH(CH 2 CH 2 OH), CH 2 OH, P(O)(OH) 2 , CONHSO 2 R 2 , SO 2 N(R 2 ) 2 , SO 2 NHR 2 ,

wherein R 2 is independently H, C 1 -C 6 alkyl, unsubstituted phenyl, or unsubstituted biphenyl.

3. The compound of claim 1 wherein B is substituted phenyl.

4. The compound of claim 2 represented by the formula

or a pharmaceutically acceptable salt thereof;

R is hydrogen or C 1-10 hydrocarbyl.

5. The compound of claim 4 wherein R is alkyl.

6. The compound of claim 3 wherein A is —(CH 2 ) m —Ar—(CH 2 ) o — wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein one CH 2 may be replaced by S or O.

7. The compound of claim 6 wherein A is —(CH 2 ) 3 Ar—, —O(CH 2 ) 2 Ar—, —CH 2 OCH 2 Ar—, —(CH 2 ) 2 OAr, —O(CH 2 ) 2 Ar—, —CH 2 OCH 2 Ar—, or —(CH 2 ) 2 OAr, wherein Ar is monocyclic interheteroarylene.

8. The compound of claim 7 wherein Ar is interthienylene.

9. The compound of claim 7 wherein Ar is interthiazolylene.

10. The compound of claim 7 wherein Ar is interoxazolylene.

11. The compound of claim 2 wherein A is 6-hexyl.

12. The compound of claim 2 wherein A is (Z)-6-hex-4-enyl.

13. A compound of claim 4 selected from the group consisting of:

(Z)-7-{(1R,2S ,3R, 5R)-5-cyano-3-hydroxy-2[4-(1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid;

(Z)-7-{(1R,2S ,3R,5R)-5-cyano-3-hydroxy-2[4-(1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid isopropyl ester; and

(Z)-7-{(1R,2S, 3R,5R)-5-cyano-3-hydroxy-2[4-(1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid methyl ester.

14. A method comprising administering a compound of claim 1 to a mammal for the treatment of glaucoma or ocular hypertension.

15. A composition comprising a compound according to claim 1 , wherein said composition is a liquid which is ophthalmically acceptable.